Myovant's Uterine Fibroid Drug Relugolix Produces Positive Data in a Long-Term Study

Myovant Sciences (NYSE: MYOV) reported positive results from the late-stage Liberty extension study testing its relugolix combination therapy, which contains relugolix, estradiol, and norethindrone acetate, in patients with uterine fibroids.